Santhera Braced For Another CHMP No In Duchenne

 
• By Lucie Ellis-Taitt

Santhera had a tumultuous 2017 and recovery is not going to be easy this year as its lead compound for the rare disease Duchenne muscular dystrophy is about to be rejected by regulators in Europe for a second time.

Straws
Rise And Fall: Santhera stumbles on CHMP rejection for Raxone • Source: Shutterstock

More from Rare Diseases

More from Scrip